Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMAC and DLI for Relapsed AML After Allo-HSCT
NCT06447090Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2024
- Primary completion
- May 2027
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone hydrochloride liposome in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete Remission Rate at 1 year. Started Apr 2024; status: recruiting.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06447090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06447090.